MedTrace Logo

Implementing ctDNA and Circular DNA in Patients With Localized Pancreatic Cancer

NCT05788744 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1000

Last updated 2026-03-27

No results posted yet for this study

Summary

The goal of this clinical trial is to investigate if plasma ctDNA and eccDNA before resection for suspicion of pancreatic ductal adenocarcinoma (PDAC) can predict early recurrence and overall survival, and to investigate if plasma ctDNA combined with CT scan and endoscopic ultrasound surveillance increases the median overall survival compared with standard-of-care surveillance.

Conditions

  • Resectable Pancreatic Cancer

Interventions

DIAGNOSTIC_TEST

ctDNA

ctDNA guided surveillance

Sponsors & Collaborators

  • Aarhus University Hospital

    collaborator OTHER

  • University of Copenhagen

    collaborator OTHER

  • Odense University Hospital

    collaborator OTHER

  • Copenhagen University Hospital at Herlev

    lead OTHER

Principal Investigators

  • Julia S Johansen, MD · Copenhagen University Hospital - Herlev and Gentofte

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-01
Primary Completion
2029-01-31
Completion
2032-01-31

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05788744 on ClinicalTrials.gov